Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Microglia-neuron communication in health and disease

NeuroTalk2Mi

Microglia are the resident immune cells of the brain, display extensive heterogeneity, and contribute to a wide range of cellular processes in both homeostasis and disease. They play a major role in the pathogenesis of Alzheimer’s disease (AD), the leading cause of dementia and a major cause of mortality worldwide. Microglia closely interact with...

Funding Programme
Start Date
End Date
Total Funding
€ 191 760
European Countries Involved

Microglia-synapse molecular interactions in neurodegenerative disorders

MicroSyn-MIND

Microglia are immune cells that monitor our brain and degrade unhealthy neurons and excess synapses. In Alzheimer’s disease (AD) however, microglia excessively destroy synapses, marking them as enticing treatment targets. AD patients accumulate cortical Amyloid-beta (Aβ) plaques and neurofibrillary tau tangles, whilst losing neurons and synapses...

Funding Programme
Start Date
End Date
Total Funding
€ 191 760
European Countries Involved

Minimally invasive endoscopes for neuronal activity monImaging-assisted single-cell specific activity monitoring and optogenetic stimulation of deep brain structures in motile and awaken animal models

WOKEGATE

Severe neuronal disorders such as dementia affect more than 1 billion people globally and account for economic burden far exceeding that of cancer. Our only chance of treating dementia is improving our understanding of how brains function at diverse levels of complexity. This will only be possible through better technologies, which already reflects...

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Modulating immune responses to mitigate neuroinflammation, bioenergetic decrease and cognitive decline in Alzheimer’s disease

immuno-ALZ

Background and rationale: Alzheimer's disease (AD) is the main cause of dementia, with substantial socio-economic burdens. Due to the absence of a cure, understanding disease mechanisms and developing new therapies is crucial. Age-related systemic and brain inflammation contributes to cognitive decline. Inhibiting prostaglandin 2 (PGE2) - PGE2...

Funding Programme
Start Date
End Date
Total Funding
€ 266 684
European Countries Involved

MRI analysis tool for early detection of dementia

MATEDD

Worldwide due to population ageing there will be 75 million patients with Alzheimer's disease by 2030. Alzheimer's is a disease described by accelerated brain ageing which leads to decline in both memory and cognitive skills, thus affecting everyday activities of those suffering. On average over 60% of patients do not receive a diagnosis and...

Funding Programme
Start Date
End Date
Total Funding
€ 75 000
European Countries Involved

MRI-based ID of the Vasculature across the Heart-Brain Axis

VascularID

Microvascular impairment is a hallmark of many of todays most burdening diseases, including forms of ischemic heart disease, stroke, and dementia. It is also the most promising candidate to explain the link between cardiovascular and brain disease (so-called heart-brain axis). However, only histology provides comprehensive assessment of the...

Funding Programme
Start Date
End Date
Total Funding
€ 1 852 430
European Countries Involved

Multi-Omics-based BIomarker Signatures of dietary Carbohydrates qUalITy and risk of chronic diseaseS.

BISCUITS

The prevalence of type 2 diabetes mellitus (T2D), cardiovascular disease (CVD), and dementia is rapidly increasing worldwide and is therefore a major public health concern. Carbohydrate intake (40-80%) represents the main source of energy in most populations and the quality more than the quantity has a large effect on health. Recently, a...

Funding Programme
Start Date
End Date
Total Funding
€ 222 727
European Countries Involved

Multimodal Brain Imaging – Gene Relationships in Alzheimer Disease: Risk and Resilience

ADRIAN

The list of genes contributing to increased risk of developing Alzheimers Disease (AD) grows every year. To date, large case-control Genome-Wide Association Studies have found 98 genetic loci associated with late-onset Alzheimer's Disease (LOAD). However, apart from a small number of genes related to familial cases, it remains largely unknown the...

Funding Programme
Start Date
End Date
Total Funding
€ 181 152
European Countries Involved

NAD+ International Scientist-training

NADIS

Nicotinamide adenine dinucleotide (NAD+) is a central redox cofactor and the limiting substrate of key metabolic enzymes. The constellation of cellular functions in which NAD+ is involved makes its availability critical for cell survival, and its depletion is a leading factor in a number of diseases in humans, ranging from rare inherited defects to...

Funding Programme
Start Date
End Date
Total Funding
€ 2 530 832
European Countries Involved

Nanofluidics for label-free detection of exosomes and protein aggregates in neurodegenerative disease research

EXO-CHIP

Microfluidics have become a powerful tool in biotechnology and life sciences, whereas the nanofluidic regime remains widely unused in industry and the clinical environment. Especially protein misfolding diseases such as Alzheimer’s, Parkinson’s and Huntington’s disease, recently experience a growing demand for single-molecule detection capabilities...

Funding Programme
Start Date
End Date
Total Funding
€ 210 911
European Countries Involved

Nanoscale organization and dynamics of ER-mitochondria contact sites upon induction of synaptic plasticity

SynERMCSs

The endoplasmic reticulum (ER) can rapidly reorganize its functional domains and inter-organelle communication sites in response to cellular demands. ER-mitochondria communication is essential for normal cell physiology, as it conveys lipid exchange, mitochondrial calcium uptake, among other vital processes for mitochondrial function. In neurons...

Funding Programme
Start Date
End Date
Total Funding
€ 206 887
European Countries Involved

Nanotechnology-enabled deep profiling of the blood and brain proteome at the intersection of neurodegeneration and neurooncology

NanoNeuroOmics

NanoNeuroOmics ambition is to bring together nanotechnology, proteomics and blood biomarker discovery at the emerging intersection of neurodegeneration and neurooncology. NanoNeuroOmics proposes a nanotechnology-based innovative solution for the integrative profiling of the blood and brain tissue proteomes to address two interconnected challenges...

Funding Programme
Start Date
End Date
Total Funding
€ 1 494 954
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).